 CHARLOTTESVILLE, VA ACCESSWIRE April 9, 2020 Adial Pharmaceuticals, Inc. NASDAQ:ADIL; ADILW, a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today provided an update on its landmark ONWARDTM Phase 3 pivotal trial of its lead drug candidate, AD04, in genetically identified subjects for the treatment of Alcohol Use Disorder AUD. The number of in-clinic visits per subject has been reduced from 19 to 8. 